Deerfield and Jintai Technology (07666) form the first strategic alliance in China to jointly promote AI-driven protein drugs and in vivo immunotherapy.

On May 28th, the global leading AI drug delivery innovation company, AiTherapeutics (07666), announced a strategic alliance with the top global healthcare investment and innovation platform Deerfield Management. This is Deerfield's first strategic alliance with a Chinese biotechnology company. The two parties will collaborate on the development of next-generation in vivo protein drugs and immunotherapies, and work together to advance the global commercialization of their collaborative pipeline. This partnership will integrate AiTherapeutics' differentiated technology in AI-driven protein engineering, in vivo immunotherapy, and programmable biologics with Deerfield's extensive industry experience in translational medicine, clinical development, and global collaborations. The two parties will deepen their cooperation around AiTherapeutics' proprietary AI nano delivery platform NanoForge and its core pipeline. In particular, a leading T cell engager (TCE) project identified and advanced to the preclinical candidate stage by AiTherapeutics' AiProtein platform will be a focus for advancement. Deerfield will explore licensing and development opportunities for this project, helping it progress into IND support studies and clinical stages. AiTherapeutics' self-developed AI nano delivery platform NanoForge uses an innovative paradigm of "dry experiments + wet experiments + intelligent body," driving four major solutions: AiLNP, AiRNA, AiProtein, and AiTEM. Deerfield is one of the most influential professional investment institutions in the global life sciences field, managing assets exceeding $16 billion and having invested in over 200 healthcare enterprises, with deep involvement in cutting-edge areas such as oncology, immunotherapy, RNA therapy, gene editing, and AI pharmaceuticals. Dr. Lai Caidabuo, Chairman and CEO of AiTherapeutics, stated that Deerfield is one of the most respected healthcare investment and innovation platforms globally, and they will fully accelerate the progress and implementation of this strategic alliance. AiTherapeutics is at the forefront of exploring precise in vivo immunotherapy globally and, together with Deerfield, will build an innovative platform with significant differentiation advantages, speeding up the development of breakthrough therapies for patients worldwide. Dr. Brian Chow, Managing Director of Deerfield, noted that AiTherapeutics continues to drive innovation in the intersection of artificial intelligence, biopharmaceuticals, and in vivo therapeutic engineering. They look forward to collaborating with the AiTherapeutics team to advance the development of innovative therapies driven by their proprietary AI platform and next-generation delivery technologies.